On the same day Anthropic staged a record-shattering IPO on Nasdaq, the artificial intelligence tech giant’s lone ...
Chroma Bio’s workforce are facing a second round of layoffs in 12 months, with the Boston biotech halving its headcount and ...
Isomorphic Labs’ big week just got bigger. Days after raising $5 billion, the AI-powered biotech has added Merck & Co. to a ...
AbbVie is twirling onto the dance floor with Disco Pharmaceuticals, offering up to $2.5 billion to work with the German ...
Teva’s R&D chief Eric Hughes, M.D., Ph.D., has resigned one week after the company showcased its push to grow its innovative ...
Despite a bumpy few months for Novartis that saw a couple of high-profile clinical setbacks, CEO Vas Narasimhan has told ...
Evaxion is halting work on its infectious disease and autoimmune programs as the Danish biotech refocuses its R&D efforts ...
Cognito Therapeutics said its phase 3 HOPE study of Spectris AD, an investigational, non-invasive, at-home Alzheimer's ...
In return for a $330 million upfront fee, Pfizer has secured the ex-China rights to three in vivo CAR-T programs that are ...
Biogen has linked its tau-targeting antisense oligonucleotide to a further slowing of clinical decline after two years, ...
Merck & Co. has stopped a trio of phase 3 blood cancer trials after one study suggested the benefits of the BTK inhibitor may ...
Vertex Pharmaceuticals has re-upped its ties with sequencing specialist Genomics in a deal worth up to $220 million, signing ...